Valuation: Norda ASA

Market Cap 513M 55.18M 47.29M 44.24M 40.45M 76.32M 5.28B 77.14M 523M 204M 2.65B 207M 203M 8.78B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 28.43M 24.36M 22.79M 20.84M 39.32M 2.72B 39.74M 270M 105M 1.37B 107M 104M 4.52B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
6 months+1.53%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 2013-04-07
Director TitleAgeSince
Chairman 54 2014-01-30
Director/Board Member 68 2013-06-19
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+6.67%+110.73% 47.66M
-0.74%+4.48%+3.74%+22.46% 51.61B
+1.01%-0.20%+493.16%+564.93% 44.89B
+0.16%+7.88%+38.41%+20.76% 42.77B
-0.66%+2.61%+20.53%+87.04% 42.58B
+0.88%-3.48%+17.20%+57.20% 31.82B
-0.12%+3.84%+32.83%+145.25% 17.33B
-0.53%+1.84% - - 16.63B
+0.58%+4.00%+7.17%+30.59% 14.76B
+1.15%+4.17%+81.94%+50.33% 14.09B
Average +0.28%+4.50%+77.96%+121.03% 27.65B
Weighted average by Cap. +0.01%+5.13%+104.76%+140.90%

Financials

2023 2024
Net sales 86.92M 9.35M 8.01M 7.49M 6.85M 12.93M 895M 13.07M 88.67M 34.48M 449M 35.09M 34.33M 1.49B 372M 39.98M 34.27M 32.06M 29.31M 55.31M 3.83B 55.89M 379M 147M 1.92B 150M 147M 6.36B
Net income 31.17M 3.35M 2.87M 2.69M 2.46M 4.64M 321M 4.69M 31.8M 12.36M 161M 12.59M 12.31M 533M 126M 13.54M 11.61M 10.86M 9.93M 18.73M 1.3B 18.93M 128M 49.96M 651M 50.85M 49.75M 2.15B
Net Debt -311M -33.47M -28.68M -26.83M -24.53M -46.29M -3.2B -46.78M -318M -123M -1.61B -126M -123M -5.32B -249M -26.75M -22.93M -21.45M -19.61M -37.01M -2.56B -37.4M -254M -98.7M -1.29B -100M -98.28M -4.26B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock